Cargando…

Effect of four monthly doses of a human monoclonal anti-FGF23 antibody (KRN23) on quality of life in X-linked hypophosphatemia

X-linked hypophosphatemia (XLH) is characterized by lower extremity deformities that lead to bone and/or joint pain that result from decreased renal tubular reabsorption leading to hypophosphatemia caused by elevated levels of fibroblast growth factor 23 (FGF23). OBJECTIVE: Validate the use of SF-36...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ruppe, Mary D., Zhang, Xiaoping, Imel, Erik A., Weber, Thomas J., Klausner, Mark A., Ito, Takahiro, Vergeire, Maria, Humphrey, Jeffrey S., Glorieux, Francis H., Portale, Anthony A., Insogna, Karl, Peacock, Munro, Carpenter, Thomas O.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2016
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4926842/ https://www.ncbi.nlm.nih.gov/pubmed/28326356 http://dx.doi.org/10.1016/j.bonr.2016.05.004

Ejemplares similares

Pharmacokinetics and pharmacodynamics of a human monoclonal anti‐FGF23 antibody (KRN23) in the first multiple ascending‐dose trial treating adults with X‐linked hypophosphatemia
por: Zhang, Xiaoping, et al.
Publicado: (2015)

FGF23, Hypophosphatemia, and Emerging Treatments
por: Imel, Erik A, et al.
Publicado: (2019)

Sustained Efficacy and Safety of Burosumab, a Monoclonal Antibody to FGF23, in Children With X-Linked Hypophosphatemia
por: Linglart, Agnès, et al.
Publicado: (2021)

Long-term Burosumab Administration Is Safe and Effective in Adults With X-linked Hypophosphatemia
por: Weber, Thomas J, et al.
Publicado: (2022)

OR29-01 Long-Term Safety in Adults with X-Linked Hypophosphatemia (XLH) Treated with Burosumab, a Fully Human Monoclonal Antibody Against FGF23: Final Results of a Phase 3 Trial
por: Perwad, Farzana, et al.
Publicado: (2020)

FGF23 and its role in X-linked hypophosphatemia-related morbidity
por: Beck-Nielsen, Signe Sparre, et al.
Publicado: (2019)

Antibody-Mediated Activation of FGFR1 Induces FGF23 Production and Hypophosphatemia
por: Wu, Ai-Luen, et al.
Publicado: (2013)

Severe Hypophosphatemia and Elevated FGF23 Level Following Zoledronic Acid Infusion
por: Betlachin, Anna, et al.
Publicado: (2021)

OR13-2 Characterizing the Impact of Burosumab on Bone Health in Children with X-Linked Hypophosphatemia: Results from Year 1 of the Disease Monitoring Program
por: Carpenter, Thomas, et al.
Publicado: (2022)

Hypophosphatemia and FGF23 tumor-induced osteomalacia in two cases of metastatic breast cancer
por: Abramson, Matthew, et al.
Publicado: (2021)

Case Report: Unexplained Mild Hypophosphatemia and Very High Serum FGF23 Concentrations
por: Bosman, Ariadne, et al.
Publicado: (2023)

An Unusually Prolonged Case of FGF23-mediated Hypophosphatemia Secondary to Ferric Carboxymaltose Use
por: Arora, Ipsa, et al.
Publicado: (2023)

Serum Levels of Lipocalin Are Lower in Adolescents With X-Linked Hypophosphatemia
por: Simpson, Christine A, et al.
Publicado: (2021)

Sharp rises in FGF23 and hypophosphatemia after intravenous iron administration do not cause myocardial damage
por: Brandenburg, Vincent, et al.
Publicado: (2020)

Clinical performance of a new intact FGF23 immunoassay in healthy individuals and patients with chronic hypophosphatemia
por: Kato, Hajime, et al.
Publicado: (2023)

SAT-LB085 First Report of Burosumab (Anti-FGF23 Monoclonal Antibody) for Rickets Complicating HRAS-Associated Cutaneous Skeletal Hypophosphatemia Syndrome
por: Smith, Pamela, et al.
Publicado: (2019)

SUN-364 Enthesophytes Are a Common Feature of FGF23-Mediated Hypophosphatemia Due to Tumor-Induced Osteomalacia
por: Gafni, Rachel Ilana, et al.
Publicado: (2020)

Murine models of HRAS-mediated cutaneous skeletal hypophosphatemia syndrome suggest bone as the FGF23 excess source
por: Ovejero, Diana, et al.
Publicado: (2023)

A computationally identified compound antagonizes excess FGF-23 signaling in renal tubules and a mouse model of hypophosphatemia
por: Xiao, Zhousheng, et al.
Publicado: (2016)

FGF23 and inflammation
por: Sharaf El Din, Usama A A, et al.
Publicado: (2017)

Musculoskeletal Features in Adults With X-linked Hypophosphatemia: An Analysis of Clinical Trial and Survey Data
por: Javaid, Muhammad Kassim, et al.
Publicado: (2021)

Enthesopathy, Osteoarthritis, and Mobility in X-linked Hypophosphatemia
por: Imel, Erik A
Publicado: (2020)

Circulating Levels of Leptin and Lipocalin-2 in Patients With X-Linked Hypophosphatemia
por: Simpson, Christine A, et al.
Publicado: (2023)

Phosphate and FGF-23
por: Jüppner, Harald
Publicado: (2011)

Characterization of FGF23-Dependent Egr-1 Cistrome in the Mouse Renal Proximal Tubule
por: Portale, Anthony A., et al.
Publicado: (2015)

Fibroblast Growth Factor 23–Induced Hypophosphatemia in Acute Leukemia
por: Reinert, Rachel B, et al.
Publicado: (2018)

Variation in the fibroblast growth factor 23 (FGF23) gene associates with serum FGF23 and bone strength in infants
por: Enlund-Cerullo, Maria, et al.
Publicado: (2023)

What are the benefits of the anti-FGF23 antibody burosumab on the manifestations of X-linked hypophosphatemia in adults in comparison with conventional therapy? A review
por: Lafage-Proust, Marie-Hélène
Publicado: (2022)

FGF23 is elevated in multiple myeloma and increases heparanase expression by tumor cells
por: Suvannasankha, Attaya, et al.
Publicado: (2015)

Effect of Burosumab Compared With Conventional Therapy on Younger vs Older Children With X-linked Hypophosphatemia
por: Ward, Leanne M, et al.
Publicado: (2022)

FGF-23 Regulates CYP27B1 Transcription in the Kidney and in Extra-Renal Tissues
por: Chanakul, Ankanee, et al.
Publicado: (2013)

FGF-23 in bone biology
por: Wesseling-Perry, Katherine
Publicado: (2009)

FGF23, Biomarker or Target?
por: Rodelo-Haad, Cristian, et al.
Publicado: (2019)

Pleiotropic Actions of FGF23
por: Erben, Reinhold G.
Publicado: (2017)

OR13-2 Burosumab Resulted in Greater Improvement in Rickets Than Conventional Therapy in Children with X-Linked Hypophosphatemia (XLH)
por: Imel, Erik, et al.
Publicado: (2019)

Serum FGF23 levels may not be associated with serum phosphate and 1,25-dihydroxyvitamin D levels in patients with Fanconi syndrome–induced hypophosphatemia
por: Goto, Shunsuke, et al.
Publicado: (2016)

Fibroblast Growth Factor 23 (FGF23) and Disorders of Phosphate Metabolism
por: Saito, Tasuku, et al.
Publicado: (2009)

PKC regulates the production of fibroblast growth factor 23 (FGF23)
por: Bär, Ludmilla, et al.
Publicado: (2019)

The Measurement and Interpretation of Fibroblast Growth Factor 23 (FGF23) Concentrations
por: Heijboer, Annemieke C., et al.
Publicado: (2022)

FGF23 Producing Mesenchymal Tumor
por: Papierska, Lucyna, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_rhceedr8fkb2gaahc1joi16c3a